Oxford BioMedica (LON:OXB)‘s stock had its “buy” rating restated by investment analysts at Peel Hunt in a report issued on Wednesday, July 18th.
Separately, Jefferies Financial Group lowered Oxford BioMedica to a “hold” rating in a research note on Wednesday, June 13th.
Oxford BioMedica traded up GBX 10 ($0.13), reaching GBX 900 ($11.65), during trading on Wednesday, according to MarketBeat.com. 59,378 shares of the company’s stock were exchanged, compared to its average volume of 6,890,000. Oxford BioMedica has a fifty-two week low of GBX 4.44 ($0.06) and a fifty-two week high of GBX 13.19 ($0.17).
In other Oxford BioMedica news, insider Lorenzo Tallarigo purchased 17,702 shares of the stock in a transaction on Wednesday, May 23rd. The stock was bought at an average cost of GBX 15 ($0.19) per share, for a total transaction of £2,655.30 ($3,437.28). Also, insider John Dawson sold 10,046 shares of the stock in a transaction dated Tuesday, August 7th. The stock was sold at an average price of GBX 890 ($11.52), for a total value of £89,409.40 ($115,740.32). Insiders have bought 18,270 shares of company stock worth $797,810 in the last ninety days.
Oxford BioMedica Company Profile
Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.
Further Reading: How do investors use RSI to grade stocks?
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.